These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 32382949)

  • 1. Tirabrutinib: First Approval.
    Dhillon S
    Drugs; 2020 Jun; 80(8):835-840. PubMed ID: 32382949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
    Liclican A; Serafini L; Xing W; Czerwieniec G; Steiner B; Wang T; Brendza KM; Lutz JD; Keegan KS; Ray AS; Schultz BE; Sakowicz R; Feng JY
    Biochim Biophys Acta Gen Subj; 2020 Apr; 1864(4):129531. PubMed ID: 31953125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Orelabrutinib: First Approval.
    Dhillon S
    Drugs; 2021 Mar; 81(4):503-507. PubMed ID: 33704654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement.
    Yu H; Truong H; Mitchell SA; Liclican A; Gosink JJ; Li W; Lin J; Feng JY; Jürgensmeier JM; Billin A; Xu R; Patterson S; Pagratis N
    SLAS Discov; 2018 Oct; 23(9):919-929. PubMed ID: 30011241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton's tyrosine kinase inhibitor, in pemphigus.
    Yamagami J; Ujiie H; Aoyama Y; Ishii N; Tateishi C; Ishiko A; Ichijima T; Hagihara S; Hashimoto K; Amagai M
    J Dermatol Sci; 2021 Sep; 103(3):135-142. PubMed ID: 34376340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tirabrutinib hydrochloride for B-cell lymphomas.
    Munakata W; Tobinai K
    Drugs Today (Barc); 2021 Apr; 57(4):277-289. PubMed ID: 33851691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semi-Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA.
    Meng A; Humeniuk R; Jürgensmeier JM; Hsueh CH; Matzkies F; Grant E; Truong H; Billin AN; Yu H; Feng J; Kwan E; Tarnowski T; Nelson CH
    Clin Pharmacol Ther; 2022 Feb; 111(2):416-424. PubMed ID: 34623640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.
    Munakata W; Ando K; Hatake K; Fukuhara N; Kinoshita T; Fukuhara S; Shirasugi Y; Yokoyama M; Ichikawa S; Ohmachi K; Gion N; Aoi A; Tobinai K
    Cancer Sci; 2019 May; 110(5):1686-1694. PubMed ID: 30815927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia.
    Sekiguchi N; Rai S; Munakata W; Suzuki K; Handa H; Shibayama H; Endo T; Terui Y; Iwaki N; Fukuhara N; Tatetsu H; Iida S; Ishikawa T; Shiibashi R; Izutsu K
    Cancer Sci; 2020 Sep; 111(9):3327-3337. PubMed ID: 32639651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.
    Caldwell RD; Qiu H; Askew BC; Bender AT; Brugger N; Camps M; Dhanabal M; Dutt V; Eichhorn T; Gardberg AS; Goutopoulos A; Grenningloh R; Head J; Healey B; Hodous BL; Huck BR; Johnson TL; Jones C; Jones RC; Mochalkin I; Morandi F; Nguyen N; Meyring M; Potnick JR; Santos DC; Schmidt R; Sherer B; Shutes A; Urbahns K; Follis AV; Wegener AA; Zimmerli SC; Liu-Bujalski L
    J Med Chem; 2019 Sep; 62(17):7643-7655. PubMed ID: 31368705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
    Narita Y; Nagane M; Mishima K; Terui Y; Arakawa Y; Yonezawa H; Asai K; Fukuhara N; Sugiyama K; Shinojima N; Kitagawa J; Aoi A; Nishikawa R
    Neuro Oncol; 2021 Jan; 23(1):122-133. PubMed ID: 32583848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
    Ringheim GE; Wampole M; Oberoi K
    Front Immunol; 2021; 12():662223. PubMed ID: 34803999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma.
    Okita Y; Kano-Fujiwara R; Nakatsuka SI; Honma K; Kinoshita M
    Exp Hematol Oncol; 2021 Apr; 10(1):29. PubMed ID: 33902692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
    Caldwell R; Liu-Bujalski L; Qiu H; Mochalkin I; Jones R; Neagu C; Goutopoulos A; Grenningloh R; Johnson T; Sherer B; Gardberg A; Follis AV; Morandi F; Head J
    Bioorg Med Chem Lett; 2018 Nov; 28(21):3419-3424. PubMed ID: 30290988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
    da Cunha-Bang C; Niemann CU
    Drugs; 2018 Nov; 78(16):1653-1663. PubMed ID: 30390220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059).
    Rule SA; Cartron G; Fegan C; Morschhauser F; Han L; Mitra S; Salles G; Dyer MJS
    Leukemia; 2020 May; 34(5):1458-1461. PubMed ID: 31827243
    [No Abstract]   [Full Text] [Related]  

  • 17. Bruton's tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances.
    Schaff L; Nayak L; Grommes C
    Leuk Lymphoma; 2024 Jul; 65(7):882-894. PubMed ID: 38597202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).
    Feng Y; Duan W; Cu X; Liang C; Xin M
    Expert Opin Ther Pat; 2019 Apr; 29(4):217-241. PubMed ID: 30888232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Fast and Clean BTK Inhibitor.
    Gabizon R; London N
    J Med Chem; 2020 May; 63(10):5100-5101. PubMed ID: 32401033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ibrutinib.
    Charalambous A; Schwarzbich MA; Witzens-Harig M
    Recent Results Cancer Res; 2018; 212():133-168. PubMed ID: 30069629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.